HC Wainwright Estimates Ardelyx's Q3 Earnings (NASDAQ:ARDX)

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Ardelyx to a loss of $0.06 per share from a projected profit of $0.05, while maintaining a Buy rating and $13 price target.
• Ardelyx reported a Q2 loss of $0.07 per share, missing the $0.05 consensus estimate, while revenue reached $120.88 million and grew 34.3% year over year.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and $15 price target, although shares opened at $4.00 and have traded near their 52-week low of $3.90.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - HC Wainwright reduced their Q3 2026 EPS estimates for Ardelyx in a note issued to investors on Friday, August 7th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter, down from their previous estimate of $0.05. HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.10) per share. HC Wainwright also issued estimates for Ardelyx's Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.26) EPS and FY2030 earnings at $1.61 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million for the quarter, compared to analysts' expectations of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 35.57%. The business's revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.08) EPS.

Other equities research analysts have also recently issued reports about the company. BTIG Research decreased their price target on Ardelyx from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday. Weiss Ratings downgraded shares of Ardelyx from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, June 29th. LADENBURG THALM/SH SH began coverage on shares of Ardelyx in a report on Tuesday, June 16th. They set a "buy" rating and a $16.00 price objective on the stock. Citigroup lowered their target price on shares of Ardelyx from $14.00 to $11.00 and set a "buy" rating for the company in a research note on Monday. Finally, Zacks Research lowered shares of Ardelyx from a "hold" rating to a "strong sell" rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Ardelyx Price Performance

Shares of ARDX stock opened at $4.00 on Tuesday. The stock's fifty day moving average price is $5.34 and its 200 day moving average price is $6.04. Ardelyx has a 1-year low of $3.90 and a 1-year high of $8.40. The company has a market cap of $996.75 million, a price-to-earnings ratio of -18.18 and a beta of 0.70. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.49 and a quick ratio of 3.28.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Ardelyx by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company's stock valued at $781,000 after purchasing an additional 4,436 shares during the period. Goldman Sachs Group Inc. grew its position in Ardelyx by 10.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company's stock valued at $11,680,000 after buying an additional 221,486 shares during the period. Focus Partners Wealth acquired a new stake in Ardelyx during the first quarter valued at $72,000. Strs Ohio acquired a new stake in Ardelyx during the first quarter valued at $135,000. Finally, Legal & General Group Plc increased its holdings in Ardelyx by 13.5% in the second quarter. Legal & General Group Plc now owns 275,344 shares of the biopharmaceutical company's stock valued at $1,080,000 after buying an additional 32,738 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company's stock.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, insider Eric Duane Foster sold 7,998 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the sale, the insider directly owned 417,972 shares of the company's stock, valued at approximately $2,620,684.44. This trade represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mike Kelliher sold 7,248 shares of Ardelyx stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total value of $45,444.96. Following the transaction, the insider owned 357,418 shares of the company's stock, valued at approximately $2,241,010.86. This represents a 1.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 24,572 shares of company stock valued at $154,066. 5.30% of the stock is currently owned by corporate insiders.

About Ardelyx

Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source